The lncRNA LENOX interacts with RAP2C to regulate metabolism and promote resistance to MAPK inhibition in melanoma. - Archive ouverte HAL Access content directly
Journal Articles Cancer Research Year : 2022

The lncRNA LENOX interacts with RAP2C to regulate metabolism and promote resistance to MAPK inhibition in melanoma.

Abstract

Abstract Tumor heterogeneity is a key feature of melanomas that hinders development of effective treatments. Aiming to overcome this, we identified LINC00518 (LENOX; LincRNA-ENhancer of OXidative phosphorylation) as a melanoma-specific lncRNA expressed in all known melanoma cell states and essential for melanoma survival in vitro and in vivo. Mechanistically, LENOX promoted association of the RAP2C GTPase with mitochondrial fission regulator DRP1, increasing DRP1 S637 phosphorylation, mitochondrial fusion, and oxidative phosphorylation. LENOX expression was upregulated following treatment with MAPK inhibitors, facilitating a metabolic switch from glycolysis to oxidative phosphorylation and conferring resistance to MAPK inhibition. Consequently, combined silencing of LENOX and RAP2C synergized with MAPK inhibitors to eradicate melanoma cells. Melanomas are thus addicted to the lncRNA LENOX, which acts to optimize mitochondrial function during melanoma development and progression.
Fichier principal
Vignette du fichier
4555.pdf (2.16 Mo) Télécharger le fichier
Origin Publication funded by an institution
Licence

Dates and versions

hal-03808749 , version 1 (20-04-2023)

Licence

Identifiers

Cite

Giovanni Gambi, Gabrielle Mengus, Guillaume Davidson, Ewout Demesmaeker, Alessandro Cuomo, et al.. The lncRNA LENOX interacts with RAP2C to regulate metabolism and promote resistance to MAPK inhibition in melanoma.. Cancer Research, 2022, ⟨10.1158/0008-5472.CAN-22-0959⟩. ⟨hal-03808749⟩
24 View
19 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More